Ligand Pharmaceuticals Inc. announced Feb. 7 the Food and Drug Administration granted its cancer drug, Targretin gel, priority review.
Ligand said it expects the FDA will complete its review of data on Targretin gel, a treatment for cutaneous T-cell lymphoma (CTCL), by June.
“We are pleased with the FDA’s decision to grant priority review status to Targretin gel,” said David E. Robinson, Ligand’s chairman, president and CEO.
If approved, Targretin gel would be Ligand’s fourth drug hitting the U.S. market.
The San Diego-based biotech firm already received FDA approval for Ontak, a treatment for lymphoma; Panretin gel, a topical treatment for AIDS-related skin lesions; and most recently for Targretin capsules, a treatment for cutaneous lesions in patients with early- and advanced-stage refractory CTCL.
CTCL is a cancer of the white blood cells involved in the body’s immune system.
It affects an estimated 16,000 to 20,000 people in the United States, Ligand said.
